Heron Therapeutics Inc
Fechado
SetorSaúde
0.32 -3.03
Visão Geral
Variação de preço das ações
24h
Mín
0.31
Máximo
0.34
Rendimento | 2.6M -5.5M |
|---|---|
Vendas | 3M 38M |
EPS | -0.03 |
Margem de lucro | -14.573 |
Funcionários | 128 |
EBITDA | 2.1M -5.5M |
Próximos Ganhos | 3 de nov. de 2026 |
|---|
Capitalização de Mercado | -36M 61M |
|---|---|
Abertura anterior | 3.35 |
Fecho anterior | 0.32 |
Sentimento de Notícias
By Acuity
46%
54%
148 / 340 Ranking em Healthcare
Heron Therapeutics Inc Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
Heron Therapeutics Inc Previsão
Sentimento
By Acuity
148 / 340 Ranking em Saúde
Sentimento de Notícias
Evidência de Tendência de Alta
Volatilidade
Abaixo da média
Volume de Notícias (RCV)
Acima da média
Informação Financeira
Custos administrativos e de venda
Custos Operacionais
Lucro antes de imposto
Vendas
Custo das vendas
Lucro bruto sobre vendas
Despesa com juros da dívida
EBITDA
Resultado Operacional
$
Sobre Heron Therapeutics Inc
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.